f 16618 (Pierre Fabre Group)
90
Structured Review
Pierre Fabre Group
f 16618
F 16618, supplied by Pierre Fabre Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+16618/par1+antagonist+f+16618/pmc03372833-67-0-14
Average 90 stars, based on 1 article reviews
F 16618, supplied by Pierre Fabre Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f+16618/par1+antagonist+f+16618/pmc03372833-67-0-14
Average 90 stars, based on 1 article reviews
f 16618 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Synthesized:Article Title: Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor α and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells. Article Snippet: Wound healing after angioplasty or stenting is associated with increased production of thrombin and the activation of protease-activated receptor 1 (PAR1).. The aim of the present study was to examine the effects of a new selective PAR1 antagonist, 2-[5-oxo-5-(4-pyridin-2-ylpiperazin-1-yl)-penta1,3-dienyl]-benzonitrile (F 16618), in restenosis and vascular smooth muscle cell (SMC) proliferation and migration using both in vivo and in vitro approaches.. Daily oral administration of F 16618 inhibited the restenosis induced by balloon angioplasty on rat carotid artery in a dose-dependent manner. Article Title: Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist Article Snippet: Reagents The following reagents were used: SFLLR peptide (Bachem, Weil am Rhein, Germany), human thrombin, RGDS peptide, PAR4 agonist peptide (Sigma Chemical, Saint Quentin Fallavier, France), collagen (Horm, Nycomed, Linz, Austria), ADP (Roche, Meylan, France) and arachidonic acid (Helena Bioscience Europe, Saint-Leu La Forêt, France). .. In Vitro:Article Title: Posters Tuesday 15 July Autonomic pharmacology Article Snippet: P053 Non-genomic effects of testosterone on contraction in the mouse vas deferens J Kennard, J Young, K Brain Department of Pharmacology, University of Oxford, Oxford, UK Several studies have demonstrated non-genomic effects of androgens on a range of tissue preparations, characterised by a short time lag and insensitivity to transcription and translation inhibitors (Falkenstein et al., 2000).. It is not known whether there are non-genomic effects of testosterone in the mouse vas deferens, an important model for studying junctional transmission.. Vasa deferentia were excised from eightto twelve-week-old male Balb/C mice (20–40 g) which had been humanely killed by an approved Schedule I method. Saline:Article Title: Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist Article Snippet: Reagents The following reagents were used: SFLLR peptide (Bachem, Weil am Rhein, Germany), human thrombin, RGDS peptide, PAR4 agonist peptide (Sigma Chemical, Saint Quentin Fallavier, France), collagen (Horm, Nycomed, Linz, Austria), ADP (Roche, Meylan, France) and arachidonic acid (Helena Bioscience Europe, Saint-Leu La Forêt, France). .. Ex Vivo:Article Title: Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist Article Snippet: Reagents The following reagents were used: SFLLR peptide (Bachem, Weil am Rhein, Germany), human thrombin, RGDS peptide, PAR4 agonist peptide (Sigma Chemical, Saint Quentin Fallavier, France), collagen (Horm, Nycomed, Linz, Austria), ADP (Roche, Meylan, France) and arachidonic acid (Helena Bioscience Europe, Saint-Leu La Forêt, France). .. |